NeoStem’s Advanced Adult Stem Cell Technology to be Featured at Upcoming Conference
Amex: NBS) (“NeoStem” or the “Company”), an international biopharmaceutical
company with operations in the U.S. and
been invited to present its adult stem cell technologies at the Stem Cell
Investor & Executive Networking Conference Event (SCIENCE) in
executives, visionary researchers and clinicians and other stakeholders to
highlight opportunities and discuss advances in the stem cell field.
Development and Regulatory Affairs, has been selected to participate in the
Harris will highlight the positive attributes of and advances in adult stem
cell research, as well as discuss the regenerative properties of very small
embryonic-like stem cells without the controversy of traditional embryonic
stem cells. The panel will be moderated by
Cell Biology and Neuroscience, Division of Life Sciences, at
CEO of BioTime, Inc., and
Chairman of the board of directors, will be a key speaker discussing
“Autologous Approaches” to stem cell therapy, including the Company’s
experience as a pioneer in the field of autologous (one’s own) adult stem cell
banking and its potential applications for future therapies. Other speakers at
this session will include
Pontifical Council for Culture will be a keynote speaker at the conference to
discuss the Church’s growing support of the scientific and medical application
of autologous adult stem cell and discuss the bioethical considerations.
NeoStem and the Pontifical Council for Culture recently announced a joint
initiative that unites their charitable organizations to expand research and
raise awareness of adult stem cell therapies, including working on multiple
collaborative activities to advance scientific research on adult stem cells,
exploring their clinical application in the field of regenerative medicine and
the cultural relevance of such a fundamental shift in medical treatment
“We are excited about another opportunity to highlight NeoStem’s industry
leading effort in the adult stem cell field, particularly with the recently
announced joint initiative with the Pontifical Council for Culture,” said Dr.
Stem Cell Investor & Executive Networking Conference Event (SCIENCE)
SCIENCE is hosted by National Securities Corporation and MD Becker
Partners. The SCIENCE program is strategically designed to unite investors
with industry executives to exchange information and highlight opportunities
in the expanding stem cell universe. The event will bring together the
founding visionary researchers, clinicians, business leaders, key investors,
and other stakeholders to offer compelling presentations, share information,
and discuss the future of the exciting field.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies,
pursuit of anti-aging initiatives and building of a network of adult stem cell
collection centers in the U.S. and
to donate and store their own (autologous) stem cells for their personal use
in times of future medical need. The Company also has licensed various stem
cell technologies, including a worldwide exclusive license to VSEL(TM)
technology which uses very small embryonic-like stem cells, shown to have
several physical characteristics that are generally found in embryonic stem
cells, and is pursuing the licensing of other technologies for therapeutic use.
NeoStem’s majority-controlled Chinese pharmaceutical operation, Suzhou Erye,
manufactures and distributes generic antibiotics in
information, please visit: http://www.neostem.com .
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management’s current expectations, as of the date of this
press release, and involve certain risks and uncertainties. Forward looking
statements include statements herein with respect to the successful
application of the Company’s technology, including VSELTM technology, to
develop adult stem cell therapies, about which no assurances can be given. The
Company’s actual results could differ materially from those anticipated in
these forward- looking statements as a result of various factors. Factors that
could cause future results to materially differ from the recent results or
those projected in forward-looking statements include the “Risk Factors”
described in the Company’s Annual Report on Form 10-K filed with the
Securities and Exchange Commission on
Quarterly Report on Form 10-q filed with the Securities and Exchange
Securities and Exchange Commission. The Company’s further development is
highly dependent on future medical and research developments and market
acceptance, which is outside its control.
For more information, please contact: NeoStem, Inc. Robin Smith, CEO Phone: +1-212-584-4174 Email: email@example.com Web: http://www.neostem.com CCG Investor Relations, Inc. Lei Huang, Account Manager Phone: +1-646-833-3417 Email: firstname.lastname@example.org Web: http://www.ccgirasia.com Crocker Coulson, President Phone: +1-646-213-1915 Email: email@example.com
SOURCE NeoStem, Inc.